华西证券股份有限公司 关于天圣制药集团股份有限公司 使用部分闲置募集资金进行现金管理的核查意见 华西证券股份有限公司（以下简称"华西证券""保荐人"）作为天圣制药 集团股份有限公司（以下简称"天圣制药""公司"）首次公开发行股票并上市 的保荐人，根据《证券发行上市保荐业务管理办法》（证监会令第 207 号）、《上 市公司监管指引第 2 号——上市公司募集资金管理和使用的监管要求（2022 年 修订）》（证监会公告〔2022〕15 号）以及《深圳证券交易所自律监管指引第 1 号——主板上市公司规范运作（2023 年 12 月修订）》（深证上〔2023〕1145 号） 等相关规定履行持续督导职责，就天圣制药拟使用部分闲置募集资金进行现金管 理的事项进行了审慎核查，核查具体情况如下： 一、募集资金基本情况 经中国证券监督管理委员会《关于核准天圣制药集团股份有限公司首次公开 发行股票的批复》（证监许可〔2017〕620 号）的核准，天圣制药公司向社会公 开发行 53,000,000.00 股普通股，每股发行价格为人民币 22.37 元，募集资金总额 为 1,185,610,000.00 元，扣除承销费、保荐费、发行登 ...

天圣制药集团股份有限公司 2024 年度内部控制审计报告 目 录 一、正文 1—2 页 内部控制审计报告 我们的责任是在实施审计工作的基础上，对财务报告内部控制的有效性发表 审计意见，并对注意到的非财务报告内部控制的重大缺陷进行披露。 三、内部控制的固有局限性 内部控制具有固有局限性，存在不能防止和发现错报的可能性。此外，由于 情况的变化可能导致内部控制变得不恰当，或对控制政策和程序遵循的程度降低， 根据内部控制审计结果推测未来内部控制的有效性具有一定风险。 第1页，共 2 页 [2025]京会兴审字第 00830032 号 天圣制药集团股份有限公司全体股东： 按照《企业内部控制审计指引》及中国注册会计师执业准则的相关要求，我 们审计了天圣制药集团股份有限公司(以下简称天圣制药公司)2024 年 12 月 31 日 的财务报告内部控制的有效性。 一、企业对内部控制的责任 按照《企业内部控制基本规范》、《企业内部控制应用指引》、《企业内部 控制评价指引》和《深圳证券交易所上市公司自律监管指引第 1 号——主板上 市公司规范运作》（以下简称规范运作指引）的规定，建立健全和有效实施内部 控制，并评价其有效性是天圣制 ...

专项说明 目 录 关于天圣制药集团股份有限公司 非经营性资金占用及其他关联资金往来情况汇总表的 一、正文 1—3 页 二、非经营性资金占用及其他关联资金往来情况 4 页 天圣制药集团股份有限公司全体股东： 我们接受委托，根据中国注册会计师审计准则审计了天圣制药集团股份有限 公司（以下简称"贵公司"）2024 年 12 月 31 日的合并及母公司资产负债表、2024 年度的合并及母公司利润表、合并及母公司现金流量表、合并及母公司股东权益 变动表以及财务报表附注（以下简称"财务报表"），并于 2025 年 4 月 25 日签发了 " [2025]京会兴审字第 00830022 号"保留意见审计报告。 根据《上市公司监管指引第 8 号——上市公司资金往来、对外担保的监管要 求》等的要求，贵公司编制了后附的 2024 年度非经营性资金占用及其他关联资金 往来情况汇总表（以下简称"汇总表"）。 关于天圣制药集团股份有限公司 非经营性资金占用及其他关联资金往来情况汇总表的 专项说明 [2025]京会兴专字第 00830016 号 编制和对外披露汇总表并保证其真实性、合法性及完整性是贵公司的责任， 我们对汇总表所载资料与我 ...

天圣制药集团股份有限公司 2024 年度财务报表审计报告 目 录 [2025]京会兴审字第 00830022 号 天圣制药集团股份有限公司全体股东： | 一、审计报告 | | 1—7 | 页 | | --- | --- | --- | --- | | 二、审计报告附件 | | | | | 1、 | 合并资产负债表 | 8—9 | 页 | | 2、 | 母公司资产负债表 | 10—11 | 页 | | 3、 | 合并利润表 | 12 | 页 | | 4、 | 母公司利润表 | 13 | 页 | | 5、 | 合并现金流量表 | 14 | 页 | | 6、 | 母公司现金流量表 | 15 | 页 | | 7、 | 合并股东权益变动表 | 16—17 | 页 | | 8、 | 母公司股东权益变动表 | 18—19 | 页 | | 9、 | 财务报表附注 | 20—121 | 页 | （一）保留意见 我们审计了天圣制药集团股份有限公司（以下简称天圣制药公司）财务报表， 包括 2024 年 12 月 31 日的合并及母公司资产负债表，2024 年度的合并及母公司利 润表、合并及母公司现金流量表、合并及母公司股东权益变动 ...

根据《上市公司独立董事管理办法》《深圳证券交易所上市公司自律监管指 引第 1 号——主板上市公司规范运作》《深圳证券交易所股票上市规则》以及《公 司章程》《独立董事工作制度》等相关规定，并结合独立董事分别向董事会提交 的《独立董事关于独立性的自查报告》，天圣制药集团股份有限公司（以下简称 "公司"）董事会就公司 2024 年度在任独立董事杨大坚先生、李定清先生、易 润忠先生在任期内的独立性情况进行评估并出具如下专项意见： 经核查独立董事杨大坚先生、李定清先生、易润忠先生在 2024 年度任期内 的任职情况以及出具的相关自查报告等内容，公司董事会认为：上述人员未在公 司担任除独立董事以外的任何职务，也未在公司主要股东担任任何职务，与公司 以及主要股东之间不存在利害关系或其他可能妨碍其进行独立客观判断的关系， 不存在其他影响独立董事独立性的情况。因此，公司独立董事符合《上市公司独 立董事管理办法》《深圳证券交易所上市公司自律监管指引第 1 号——主板上市 公司规范运作》《深圳证券交易所股票上市规则》等相关制度规定及《公司章程》 中对独立董事独立性的相关要求。 天圣制药集团股份有限公司董事会 对独立董事独立性评估的 ...

天圣制药集团股份有限公司 2024 年度独立董事述职报告 本人已向公司递交了独立性自查情况表，按照监管规则进行了独立性自查。 报告期内，本人具备中国证监会《上市公司独立董事管理办法》所要求的独立性， 不存在影响独立性的情况。 二、独立董事年度履职情况 （一）出席董事会、股东大会会议情况 各位股东及股东代表： 本人作为天圣制药集团股份有限公司（以下简称"天圣制药"、"公司"） 独立董事，本人严格按照《公司法》《证券法》《上市公司独立董事管理办法》 《深圳证券交易所股票上市规则》《深圳证券交易所上市公司自律监管指引第 1 号——主板上市公司规范运作》《公司章程》及《独立董事工作制度》等相关法 律及规章指引的规定和要求，诚信、勤勉、独立地履行独立董事职责，积极出席 相关会议，维护公司利益和股东合法权益，对公司规范、稳定、健康地发展起到 了积极的推动作用。现将本人在 2024 年度本人工作情况向各位股东及股东代表 进行汇报。 一、独立董事基本情况 （一）个人工作履历、专业背景以及兼职情况 易润忠，1971 年 8 月出生，中国国籍，无境外永久居留权，重庆大学机电 控制及自动化硕士学位，正高级工程师，重庆科技学院教授、 ...

天圣制药集团股份有限公司 2024 年度独立董事述职报告 独立董事 杨大坚 各位股东及股东代表： 本人作为天圣制药集团股份有限公司（以下简称"天圣制药"、"公司"） 独立董事，自任职以来，严格按照《公司法》《证券法》《上市公司独立董事管 理办法》《深圳证券交易所股票上市规则》《深圳证券交易所上市公司自律监管 指引第 1 号——主板上市公司规范运作》《公司章程》及《独立董事工作制度》 等相关法律法规及规章指引的规定和要求，诚信、勤勉、独立地履行独立董事职 责，积极出席相关会议，维护公司利益和股东合法权益，对公司规范、稳定、健 康地发展起到了积极的推动作用。现将本人在 2024 年度的工作情况向各位股东 及股东代表进行汇报。 一、独立董事基本情况 （一）个人工作履历、专业背景以及兼职情况 杨大坚，1960 年 2 月出生，中国国籍，无境外居留权，香港理工大学药物 化学专业博士，重庆市中药研究院首席科学家。曾获国务院特殊贡献专家奖、编 著出版了《名贵中药材鉴别》。曾任重庆市中药研究院副研究员，香港理工大学 中药研究总监，及重庆市中药研究院院长，并曾于 2013 年 12 月至 2015 年 1 月 担任天圣制药集团 ...

（一）个人工作履历、专业背景以及兼职情况 李定清，1963 年 5 月出生，中国国籍，无境外居留权，西南大学经济管理 专业硕士，重庆工商大学会计学院教授、硕士研究生导师。曾获重庆市教学成果 一等奖 2 项、重庆市高等教育质量工程 2 项（项目负责人）、获重庆工商大学 首届"教学名师"称号，2013 年《会计学原理》（课程负责人）获重庆市精品 资源共享课程，2022 年获重庆市教学成果特等奖 1 项。曾任重庆商学院财务处 副处长、校办产业处副处长、财务会计系副主任，重庆工商大学应用技术学院院 长、会计学院院长。现任重庆市建设会计学会副会长，现任重庆市泓禧科技股份 有限公司、四川银钢一通凸轮科技股份有限公司、天圣制药集团股份有限公司独 立董事。 报告期内在董事会专门委员会任职情况：任审计委员会主任委员、提名委员 会委员、薪酬与考核委员会委员、战略委员会委员。 （二）独立性情况说明 2024 年度独立董事述职报告 独立董事 李定清 各位股东及股东代表： 本人作为天圣制药集团股份有限公司（以下简称"天圣制药"、"公司"） 独立董事，自任职以来，严格按照《公司法》《证券法》《上市公司独立董事管 理办法》《深圳证券交易所 ...

Financial Performance - The company's revenue for Q1 2025 was ¥115,533,088.70, a decrease of 21.93% compared to ¥147,987,552.62 in the same period last year[5] - The net loss attributable to shareholders was ¥12,416,708.34, an improvement of 39.32% from a loss of ¥20,461,696.10 in the previous year[5] - Net profit for the period was a loss of ¥12,537,029.71, compared to a loss of ¥20,731,689.79 in the previous period, showing an improvement of approximately 40%[20] - The company reported a total asset of CNY 2,717,977,142.99 as of March 31, 2025, a slight decrease from CNY 2,736,124,198.16 at the beginning of the period[15] - Total operating revenue decreased to ¥115,533,088.70 from ¥147,987,552.62, a decline of approximately 22%[19] - Total operating costs reduced to ¥140,612,164.96 from ¥173,317,426.29, a decrease of about 19%[19] Cash Flow - The net cash flow from operating activities increased significantly by 831.46%, reaching ¥31,794,300.40 compared to ¥3,413,366.26 in the same period last year[5] - Cash flow from operating activities generated ¥31,794,300.40, significantly up from ¥3,413,366.26 in the previous period[21] - Cash flow from investment activities showed a net outflow of ¥5,598,162.05, an improvement from a net outflow of ¥12,308,817.04 in the previous period[21] - Net cash flow from financing activities was $1,431,099.46, a significant decrease from $106,889,610.07 in the previous period[22] - Cash inflows from financing activities totaled $93,300,000.00, down from $167,000,000.00 year-over-year[22] - Cash outflows for debt repayment amounted to $87,850,000.00, an increase from $56,100,000.00 in the previous period[22] Assets and Liabilities - The total assets at the end of the reporting period were ¥2,717,977,142.99, a slight decrease of 0.66% from ¥2,736,124,198.16 at the end of the previous year[5] - Current assets totaled CNY 705,046,116.30, showing a marginal increase from CNY 702,436,533.60[15] - The total liabilities decreased slightly to CNY 716,326,000.35 from CNY 721,802,602.07, reflecting a reduction of about 0.8%[16] - The company's equity remained stable at CNY 1,400,779,329.86, unchanged from the previous period[16] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 11,396, with the largest shareholder holding 32.89% of the shares[10] - The company's weighted average return on equity was -0.62%, an improvement from -0.98% in the previous year[5] Research and Development - Research and development expenses rose by 42% year-on-year, driven by the advancement of new projects and drug re-registration[11] - Research and development expenses increased to ¥8,201,323.83 from ¥5,779,375.24, representing a rise of about 42%[19] Regulatory and Compliance - The company has not received any conclusive opinions or decisions from the China Securities Regulatory Commission regarding the ongoing investigation[14] - The company will actively cooperate with the regulatory body during the investigation period[14] - The company has not audited its first-quarter report for 2025[23] - The new accounting standards will be implemented starting in 2025[23] Other Financial Metrics - The company reported a decrease in accounts receivable from CNY 120,099,455.35 to CNY 94,754,796.53, a decline of approximately 21.1%[15] - The company’s inventory decreased from CNY 106,799,072.77 to CNY 100,225,778.99, a reduction of about 6.2%[15] - The company recorded a 244% increase in other income, primarily from a significant VAT refund received this period[11] - The company reported a decrease in sales expenses to ¥39,291,462.43 from ¥49,164,808.86, a reduction of approximately 20%[19] - The company recorded an investment loss of ¥558,811.98, contrasting with a gain of ¥35,587.88 in the previous period[19] - The basic and diluted earnings per share improved to -0.0390 from -0.0643, indicating a reduction in loss per share[20] - Cash and cash equivalents increased to CNY 294,493,873.46 from CNY 270,419,234.88, representing an increase of approximately 8.0%[15] - Short-term borrowings rose significantly to CNY 115,109,694.44 from CNY 80,080,055.56, indicating a 43.7% increase[16] - Other cash outflows related to financing activities were $425,000.00, down from $1,161,083.39 year-over-year[22]

Financial Performance - The company's operating revenue for 2024 was approximately ¥569.71 million, a decrease of 1.66% compared to ¥579.33 million in 2023[19]. - The net profit attributable to shareholders for 2024 was approximately -¥87.40 million, showing an improvement of 6.09% from -¥93.07 million in 2023[19]. - The cash flow from operating activities for 2024 was approximately ¥50.15 million, a significant increase of 304.17% compared to -¥24.56 million in 2023[19]. - The total assets at the end of 2024 were approximately ¥2.74 billion, a decrease of 2.66% from ¥2.81 billion at the end of 2023[19]. - The net assets attributable to shareholders at the end of 2024 were approximately ¥2.01 billion, down 4.10% from ¥2.09 billion at the end of 2023[19]. - The basic earnings per share for 2024 was -¥0.2749, an improvement of 6.08% from -¥0.2927 in 2023[19]. - The company reported a decrease in net profit after deducting non-recurring gains and losses, amounting to approximately -¥109.53 million in 2024, a decline of 6.24% from -¥103.10 million in 2023[19]. - The weighted average return on net assets for 2024 was -4.27%, slightly improved from -4.36% in 2023[19]. Revenue Breakdown - The company's total revenue for Q1 was approximately 148 million, Q2 was about 133 million, Q3 was around 121 million, and Q4 reached approximately 167 million[23]. - The revenue from self-manufactured oral solid preparations increased by 11.49% to ¥256,633,167.71, accounting for 45.05% of total revenue[61]. - The revenue from self-manufactured small volume injections decreased by 24.40% to ¥143,397,102.67, accounting for 25.17% of total revenue[61]. Cash Flow and Investments - Net cash flow from operating activities improved significantly to ¥50,146,536.51 in 2024, compared to a negative cash flow of ¥24,561,754.07 in 2023, an increase of 304.17%[77]. - Cash flow from investing activities showed a net inflow of ¥5,568,663.15 in 2024, a turnaround from a net outflow of ¥82,080,011.17 in 2023, an increase of 106.78%[77]. - Cash flow from financing activities increased significantly to ¥50,557,204.74 in 2024, compared to a negative cash flow of ¥11,203,509.75 in 2023, an increase of 551.26%[77]. - Total cash and cash equivalents increased by ¥106,272,404.40 in 2024, reversing a decrease of ¥117,845,274.99 in 2023, a change of 190.18%[77]. Research and Development - The company has established a specialized research platform for improved new drug development, enhancing its capabilities in traditional Chinese medicine and chemical drugs[38]. - The research and development model includes both independent and collaborative approaches, with partnerships established with several universities and research institutions[38]. - The company is currently developing several new products, including sodium bicarbonate injection and vitamin B6 injection, aimed at expanding its product line[74]. - R&D investment decreased to ¥22,752,050.49 in 2024 from ¥30,916,051.19 in 2023, a decline of 26.41%[75]. - R&D expenditure as a percentage of operating revenue fell to 3.99% in 2024 from 5.34% in 2023, a decrease of 1.35%[75]. Production and Quality Control - The company emphasizes quality control in production, adhering to national drug management laws and regulations[41]. - The company has implemented a comprehensive quality management system, ensuring all materials undergo strict quality inspections before production[43]. - The company has a strong focus on quality management, with Mr. Jiang Changhong serving as the Quality Management Department Head[141]. - The company has established a robust management team with a mix of academic and practical experience in the pharmaceutical industry[139]. Market and Strategic Initiatives - The company is focused on modernizing its pharmaceutical operations, integrating drug research, production, and sales[33]. - The company plans to enhance its marketing efforts and develop the "Tian Sheng Cloud" APP for internet pharmaceutical sales[57]. - The company is actively pursuing market expansion strategies to enhance its competitive position in the pharmaceutical industry[101]. - The company plans to launch its own internet pharmaceutical sales platform by 2025, leveraging AI tools to enhance sales and brand influence[45]. Governance and Compliance - The company maintained strict compliance with relevant laws and regulations, ensuring effective corporate governance and protecting investor interests[126]. - The company has established a market value management system and approved a valuation enhancement plan to improve its market standing[123]. - The company has a dedicated financial department that operates independently, ensuring sound financial management and decision-making[131]. - The company has established a robust internal audit system to enhance risk control and internal supervision[129]. Environmental Responsibility - The company has invested a total of 1.9336 million yuan in environmental protection during the reporting period, including 0.4992 million yuan for operation and maintenance of environmental facilities and 1.3353 million yuan for upgrading the wastewater treatment station[176]. - The company has implemented the "Three Simultaneities" principle for all construction projects, ensuring compliance with environmental impact assessments[168]. - The company has established an emergency response plan for environmental incidents, which has been reviewed by experts and aims to minimize environmental risks from accidents[175]. - The company has successfully managed its wastewater discharge, with all monitored pollutants reported as not exceeding the standards[170]. Social Responsibility - The company emphasizes its commitment to social responsibility, focusing on economic benefits while protecting the rights of stakeholders and participating in public welfare[178]. - The company provides monthly financial assistance of 1,000 yuan to a sick child in Chongqing, reducing the family's burden until the child graduates from university[182]. - The company has established a strategic partnership with local communities to promote rural revitalization through the development of traditional Chinese medicine resources[183]. Risk Management - The company recognizes R&D risks, including potential misalignment with market needs and regulatory challenges, and is focused on optimizing its R&D processes[117]. - The pharmaceutical industry faces significant policy risks, including stricter regulations and cost control measures, which could impact future development[115]. - The company is addressing drug price risks due to policy-driven price reductions and market competition by enhancing cost control and marketing strategies[119]. Shareholder Engagement - The company emphasizes the protection of shareholder rights, ensuring equal treatment for all shareholders, especially minority shareholders, during significant decision-making processes[179]. - The company actively engages with investors through various channels, including an investor hotline and performance briefings, to ensure transparent communication[179]. - The company held its annual general meeting on May 16, 2024, with a participation rate of 6.45% from investors[133].